We aimed to identify prognostic factors for AIDS-associated disseminated histoplasmosis. In a multivariate analysis, we found that dyspnea, a platelet count of !100,000 platelets/ mm 3 , and lactate dehydrogenase levels of 12 times the upper limit of the normal range were significantly independently associated with the death of the patient during the first 30 days of antifungal treatment.
We aimed to identify prognostic factors for AIDS-associated disseminated histoplasmosis. In a multivariate analysis, we found that dyspnea, a platelet count of !100,000 platelets/ mm 3 , and lactate dehydrogenase levels of 12 times the upper limit of the normal range were significantly independently associated with the death of the patient during the first 30 days of antifungal treatment.
Since 1987, disseminated histoplasmosis (DH) has been included among the AIDS-defining infections. It generally occurs when a patient's CD4 + T lymphocyte count is !100 cells/mm 3 . The most frequently infected organs are the lungs and hematopoietic organs, although all organs are susceptible. Without treatment, this disease has a rapidly fatal course.
It is currently widely accepted that amphotericin B should be given as the first-line therapy in treating severe forms of DH [1] [2] [3] [4] [5] [6] [7] . In other cases, itraconazole may be used. The advantages of itraconazole therapy over amphotericin B therapy include the lower toxicity of itraconazole and the possibility of administering itraconazole orally. The factors indicative of severity have been defined for DH in general. However, only 1 retrospective study has evaluated the prognostic factors for AIDS-associated DH [8] .
The aim of this study was to investigate a number of potentially prognostic factors for AIDS-associated DH, in order to make it possible for the clinician to determine more precisely the severity of the illness and to guide the clinician's choice concerning the initial therapy most appropriate for a given patient (i.e., amphotericin B or itraconazole).
In French Guiana, the prevalence of HIV is high-1.3% among pregnant women in 1995 [9] -and histoplasmosis is endemic. An epidemiological study reported that 30% of the histoplasmin skin tests carried out on European soldiers who had lived in French Guiana for 1 year had positive results [10] .
Patients and methods. We carried out a prospective study among HIV-positive patients presenting with histoplasmosis to determine the prognostic factors associated with death within 1 month after starting antifungal treatment. The criterion we considered (i.e., death of the patient) was treated as a qualitative variable with 2 classes: death within 30 days after starting antifungal treatment, or survival for the whole of that period (i.e., no death during the first 30 days of antifungal treatment).
The study was carried out between March 1994 and June 2002. All three hospitals in French Guiana, including 5 departments responsible for the treatment of HIV-infected patients, participated in this study.
The inclusion criteria were as follows. First, the patient needed to be experiencing their first episode of histoplasmosis. Second, the histoplasmosis needed to be confirmed by у1 of the following 3 methods: positive findings on a direct examination of May-Grunwald-Giemsa-stained smears, a positive culture, or positive findings of a histological examination. Third, the patient's HIV infection needed to be confirmed by Western blotting. Fourth, the patient needed to be receiving antifungal treatment for histoplasmosis. Fifth, the patient needed to be 115 years old. The inclusion date was the date on which antifungal treatment was begun. Patients lost to follow-up in the first 30 days following inclusion were excluded from the analysis. Data were censored after 1 June 2002.
The choice of first-line antifungal treatment (i.e., amphotericin B or itraconazole) was made by the treating physician on the basis of an assessment of the severity of histoplasmosis and state of renal function. Amphotericin B was given intravenously by central catheter at a dosage of 0.7 mg/kg per day, and itraconazole was given orally at a dosage of 400 mg per day.
The prognostic factors studied were as follows. Demographic factors were age, sex, and geographic origin. Follow-up factors were type of antifungal treatment, preexisting antiviral treat- ment (if the patient was treated for у1 month), and associated infections. Clinical and medical imaging factors included the following: dyspnea, defined as a respiratory frequency of 120 breaths per minute with respiratory distress; pulmonary forms, defined as the presence of clinical (e.g., cough or pain) and/or radiological pulmonary signs; lymphoid form, defined as the presence of superficial adenopathies 12 cm in diameter or the presence of deep adenopathies detected on a chest radiograph, by abdominal ultrasonography, or by CT; and cutaneous and/ or mucosal forms, defined as the presence of skin lesions or lesions of the buccal mucous membrane, confirming the presence of Histoplasma organisms. The laboratory values studied were CD4 + T lymphocyte count, lactate dehydrogenase (LDH), alkaline phosphatase, apartate aminotransferase (AST), Creactive protein (CRP), serum creatinine, hemoglobin, polymorphonuclear neutrophil count, and platelet count.
Using Epi Info 6.0 software (Centers for Disease Control and Prevention), we began by carrying out univariate analysis for each of the possible prognostic factors for death within 30 days of starting antifungal treatment. We then carried out multivariate analysis by step-wise logistic regression in descending order using the variables identified as associated with early death in univariate analysis ( in univariate analysis), us-P ! .05 ing the EGRET program (Cytel Software). The variables with in multivariate analysis were considered to be indepen-P ! .05 dently associated with risk of early death.
Results. During the study period, 82 cases of DH were confirmed in HIV-positive patients. The sex ratio (men to women) was 2.21:1, and the median age of the patients was 38 years. Table 1 summarizes the demographic characteristics of the patients. Table 2 summarizes the clinical classification and microbiological data leading to the diagnosis of histoplasmosis.
The principal sites of histoplasmosis were as follows: ganglia, in 47.6% of patients; pulmonary system, 42.7%; and skin and/ or mucosa, 13.4%. Dyspnea was observed in 17.1% of patients, and a concurrent illness at the time of histoplasmosis diagnosis was noted in 31.7% of patients.
The following laboratory abnormalities were observed: increases in LDH activity (observed in 87.5% of patients), AST activity (in 79.3%), alkaline phosphatase activity (in 52.5%), and CRP levels (in 92%). Thrombocytopenia was observed in 41.5% of patients, anemia in 97.6%, and neutropenia in 28%. The median CD4 + T lymphocyte count was 45 cells/mm 3 (range, 2-355), and 77.8% of patients had CD4 + T lymphocyte counts of !100 cells/mm 3 . Histoplasmosis was treated with itraconazole in 73.2% of cases and with amphotericin B in 26.8% of cases; 17.1% of the patients were taking antiretroviral medication. Eighteen (22%) of the patients died within 30 days after the initiation of antifungal treatment. Fourteen of these patients died in the first 15 days, and 9 died in the first 7 days.
We evaluated the severity of histoplasmosis, as described by Wheat [8] , and the results are summarized in table 3. Fifteen patients met the criteria for severe histoplasmosis (table 3) at the time of inclusion in the study. The mortality rate was high among those patients with cases of severe histoplasmosis (12 of 15 patients), and was higher among patients treated with itraconazole (4 of 4 patients) than among patients treated with amphotericin B (8 of 11 patients). Four of the 15 patients with severe histoplasmosis had renal failure at inclusion, 6 had shock, and 9 had respiratory failure. Renal failure occurred in 6 patients treated with amphotericin B.
The results of univariate analysis are summarized in table 4. For multivariate analysis, all the variables found to be associated with early death in univariate analysis ( were included P ! .05) in the initial model. CRP concentration was not included in the model because there were too many missing data. In the ). P p .04 Discussion. The factors potentially indicative of severity that were identified by univariate and multivariate analysis in our study differ from those identified by Wheat et al. [8] , which is the only other published study on prognostic factors for AIDS-associated DH. The retrospective study by Wheat et al. [8] , which included 155 patients treated with amphotericin B, found associations in multivariate analysis between AIDSassociated DH and high creatinine concentration in serum, low albumin concentration in serum, and the previous receipt of treatment with zidovudine. The criteria used to define severity differed from those in our study. In their study [8] , these criteria were the death of the patient from histoplasmosis, occurrence of shock, or occurrence of respiratory failure with intubation. Serum histoplasma levels, which cannot be determined in France and French Guiana, are one of the important tools for diagnosis of histoplasmosis. However, many data were missing in the Wheat et al. [8] study, particularly data for LDH activity.
In our study, multivariate analysis demonstrated associations between dyspnea, thrombocytopenia, an increase in LDH activity, and early death. Dyspnea, which is frequently associated with pulmonary involvement visible on radiograph, constitutes a sign of the severity of the disease in the lungs. It indicates the presence of severe interstitial syndromes that are similar, clinically and radiologically, to the symptoms of pneumocystosis. The association between thrombocytopenia and early death may be due to cases of hemophagocytosis, disseminated intravascular coagulation, or bone marrow suppression. An increase in LDH activity in patients with histoplamosis was first described as being associated with more severe forms of AIDSassociated DH in 1993 [11] . Another study concluded that high LDH levels (11000 IU/L) should orient diagnosis towards DH [12] . The increase in LDH levels may be associated with a hemophagocytosis syndrome. Six cases, including 3 deaths, have been described as complications of DH with, in each case, high LDH levels (11000 IU/L) [13] . However, in our series of patients, we observed only 1 case of hemophagocytosis.
In univariate analysis, we found that the rate of mortality was higher among patients treated with amphotericin B than among those treated with itraconazole. This variable was regarded as a confounding factor. These results, obtained with the treatment that is classically cited as the most effective, are due to the preferential use of amphotericin B to treat the most severe cases. Thus, among patients with severe histoplasmosis, the frequency of early death was lower among patients treated with amphotericin B (8 of 11 patients) than among patients treated with itraconazole (4 of 4 patients). These results confirm the necessity of using amphotericin B as the first-line treatment for severe histoplasmosis.
In conclusion, the presence of dyspnea, platelet counts of !100,000 platelets/mm 3 , and levels of LDH activity 12 times the upper limit of the normal range should be added to the list of classic severity factors for DH, a list that includes hypotension, a major change in general state, major denutrition with hypoalbuminemia, respiratory failure, and associated renal insufficiency.
